查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1542914

全球心肌肌钙蛋白市场 - 2024-2031

Global Cardiac Troponin Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

心肌肌钙蛋白市场规模

全球心肌肌钙蛋白市场在 2023 年达到 41.9 亿美元，预计到 2031 年将达到 95.6 亿美元，2024-2031 年预测期间复合年增长率为 11.2%。

心肌肌钙蛋白通常是检测心肌损伤的测试。肌钙蛋白是一种蛋白质，仅在心肌受损（如心臟病发作）时才会在血液中出现。肌钙蛋白升高的其他原因也存在，但心臟病发作是最常见的。此测试不能测量血液中正常情况下的少量肌钙蛋白。肌钙蛋白 T 高度敏感 (hs-TnT)，已用于进阶测试。

心肌肌钙蛋白市场动态

全球心肌肌钙蛋白市场的成长是由技术进步、人口老化、心血管疾病盛行率上升、患者意识提高以及患者医疗支出增加所推动的。

心血管疾病盛行率的增加推动了市场的成长

人们对心血管疾病和医疗基础设施的认识不断提高，推动了全球市场的发展。根据世界卫生组织（WHO）的数据，心血管疾病是全世界死亡的主要原因。每年约有 1790 万人患有心血管疾病。五分之四以上的CVD 死亡是由于心臟病发作和中风造成的，其中三分之一的死亡发生在70 岁以下的人群中。发展。

心肌肌钙蛋白是一种已确定的生物标记物，可以影响急性冠状动脉综合症患者护理的改变。肌钙蛋白从受损的心肌释放到血液中。新的高灵敏度血液检测可以在症状出现后立即检测到非常低的肌钙蛋白水平。心电图 (ECG) 可测量心臟的电活动，并可显示心臟病发作时的异常情况。

此外，市场参与者正在采取合作和产品发布等市场策略。例如，2022 年 6 月，LumiraDx Limited 宣布其产品组合多元化，其 D-二聚体测试和 NT-proBNP 测试获得了 CE 标誌。后者预计于 2022 年底实现商业化，预计将有助于临床决策。

与心肌肌钙蛋白相关的副作用将阻碍市场的成长

然而，与心肌肌钙蛋白或骨骼损伤等生物标记相关的有限特异性和副作用阻碍了市场的成长。

COVID-19对心肌肌钙蛋白市场的影响分析

COVID-19 的影响对全球心肌肌钙蛋白市场产生了重大影响。根据2021 年10 月发表在Nature Reviews Cardiology 上的文章，中度至重度COVID-19 患者的心血管併发症和心臟损伤的证据（肌钙蛋白水平升高和左心室射血分数降低）。有心血管疾病的患者可能更容易出现心血管併发症。疾病的患者高出三倍。

此外，COVID-19 患者可能有发生心臟併发症的风险，尤其是急性心臟损伤和心律不整；急性心肌损伤在患有心血管疾病的患者中可能更常见，并且与发病率和死亡率增加有关。

另一方面，根据美国心臟学会的数据，2020 年，COVID-19 感染患者肌钙蛋白结果异常的频率和非特异性，建议临床医生仅在诊断​​为急性心肌梗塞时才测量肌钙蛋白。环境中进行评估。如果没有支持证据，肌钙蛋白异常不应被认为是急性心肌梗塞的证据。

心肌肌钙蛋白市场細項分析

预计在预测期内（2023-2030 年），即时检测领域将以最快的复合年增长率成长

按类型：

肌钙蛋白I

肌钙蛋白T

其他的

按测试地点：

实验室测试

护理点测试

即时检测领域占据最大的市场份额。健康记录即时检测系统的日益普及预计将在预测期内提振市场。根据 2020 年 11 月在《实用实验室医学》上发表的文章，认证和监管标准凸显了将 POC 测试结果整合到患者电子病历中的需求不断增长。这提高了 POCT 结果的可获取性、监测和趋势的能力、防止不必要的重复测试并为患者结果提供证据。

由于POCT 结果用于做出临床决策，因此重要的是记录结果以及相关参考区间、测量单位、临界值（如果适用）、测试日期和时间，并且还可以追溯到设备序号、操作员识别号、试剂批号和品质控制 (QC) 结果。 POCT 结果也应与其他中心实验室结果明确区分开来，以避免混淆和不同分析方法的结果趋势。 POCT 目前已成为所有医院的常规检查，并已成为其他各种医疗机构中病患照护的标准。透过 POCT 可以准确地检测心肌肌钙蛋白。

按申请：

急性冠状动脉综合症

心肌梗塞

充血性心臟衰竭

其他的

透过最终用户：

医院

诊断中心

心肌肌钙蛋白市场地域份额

北美地区占据全球心肌肌钙蛋白市场最大的市场份额

按地区：

北美洲

拉丁美洲

欧洲

亚太地区

中东和非洲

北美在心肌肌钙蛋白市场上占据主导地位，预计在预测期内将呈现类似的趋势。该市场是由心臟病诊断需求的增加和心臟生物标记的进步等因素所推动的。

根据疾病管制与预防中心的数据，2020 年，美国约有 2,010 万名 20 岁及以上的成年人患有 CAD（约 7.2%）。心血管疾病患者的增加导致该地区市场的需求增加，从而推动了该地区的市场。

此外，市场参与者也在美国地区提供产品。例如，Quidel 公司提供 TriageTrueTM 高灵敏度肌钙蛋白 I 测试，用于定量测定 EDTA 抗凝血全血和血浆样本中的肌钙蛋白 I。此测试将与 Quidel 的 Triage MeterPro 仪器系统一起使用，作为心肌梗塞 (MI) 诊断的辅助手段。

心肌肌钙蛋白市场公司与竞争格局

心肌肌钙蛋白市场是本地和全球公司竞争适度的市场。为市场成长做出贡献的一些主要参与者包括 Biomerieux、Beckman Coulter、Siemens Healthcare、Roche、Fujirebio、Abbott、LifeSign、Alere 和 Singulex 等。主要参与者正在采取多种成长策略，例如产品发布、收购和合作，为全球心肌肌钙蛋白市场的成长做出贡献。

例如，

2021 年 4 月，罗氏宣布了两种关键心臟生物标记 (cTnT-hs) 的一系列五种新预期用途，采用 Elecsys 技术，该技术具有 NT-proBNP 和高度敏感的心肌肌钙蛋白 T。

生物梅里埃

概述 ：

生物梅里埃是法国跨国生物技术组织，成立于1963年，总部位于法国。它提供创新的产品和服务，以满足全球解决方案的需求。

产品组合：

VIDAS 高敏感肌钙蛋白 I：它对于优化急性冠状动脉综合症 (ACS) 的治疗很有帮助。它为诊断和风险分层提供了高水准的性能，并在 2 小时内提供诊断。

全球心肌肌钙蛋白市场报告将提供约 40 多个市场资料表、45 多个数字和 200（大约）页数。

目录

第 1 章：市场方法论与范围

  • 研究方法
  • 报告的研究目的和范围

第 2 章：市场定义与概述

第 3 章：执行摘要

第 4 章：市场动态

  • 市场影响因素
    • 司机
      • 对诊断心血管疾病的心臟生物标记的需求不断增长
      • 急性冠状动脉综合症盛行率上升
    • 限制：
      • 采集样本缺乏所需的精度
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析

第 6 章：COVID-19 分析

第 7 章：按类型

  • 肌钙蛋白I
  • 肌钙蛋白T

第 8 章：按测试地点

  • 实验室测试
  • 护理点测试

第 9 章：按申请

  • 急性冠状动脉综合症
  • 心肌梗塞
  • 充血性心臟衰竭
  • 其他的

第 10 章：最终用户

  • 医院
  • 诊断中心
  • 其他的

第 11 章：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太地区其他地区
  • 中东和非洲

第 12 章：竞争格局

  • 主要进展和策略
  • 公司股份分析
  • 产品基准化分析

第 13 章：公司简介

  • Biomerieux
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务概览
  • Beckman Coulter
  • Siemens Healthcare
  • Roche
  • Fujirebio
  • Abbott
  • LifeSign
  • Alere
  • Singulex(*LIST NOT EXHAUSTIVE)

第 14 章：数据M

简介目录
Product Code: CD1114

Cardiac Troponin Market Size

The Global Cardiac Troponin Market reached US$ 4.19 billion in 2023 and is expected to reach US$ 9.56 billion by 2031, growing at a CAGR of 11.2% during the forecast period 2024-2031.

Cardiac troponin generally is a test that detects damage to the heart muscle. Troponin is a protein that occurs in the blood only when the heart muscle is damaged, as in a heart attack. Other reasons for elevated troponin exist, but a heart attack is the most familiar. The test does not measure the low amounts of troponin normally in blood. Troponin T is highly sensitive (hs-TnT) and has been used for advanced tests.

Cardiac Troponin Market Dynamics

The global cardiac troponin market growth is driven by technological advancements, an increasingly aging population, a rising prevalence of cardiovascular patients, improving patient awareness, and rising patient healthcare expenditure.

An increasing prevalence of cardiovascular disease drives the market growth

The rising awareness of the cardiovascular disease and healthcare infrastructure drive the global market. As per the World Health Organization (WHO), cardiovascular disease is the leading cause of death worldwide. Each year around 17.9 million people suffer from cardiovascular disease. More than four of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths happen prematurely in people under 70. Rising patients with the disease need to diagnose the disease drives the market.

Cardiac troponin is an identified biomarker that can impact a change in the care of a patient with acute coronary syndrome. Troponin protein is released from damaged heart muscle into the bloodstream. New high-sensitivity blood tests allow the detection of a very low troponin level soon after the onset of symptoms. The electrocardiogram (ECG) measures the heart's electrical activity and can show abnormalities in a heart attack.

In addition, the market players are adopting the market strategies such as collaboration and product launches. For instance, in June 2022, LumiraDx Limited announced the diversification of its portfolio with a CE Mark for its D-Dimer test and NT-proBNP test. The commercialization of the latter is projected by the end of 2022, which is expected to facilitate clinical decision-making.

The side effects associated with cardiac troponin will hamper the growth of the market

However, limited specificity and side effects associated with cardiac troponin or biomarkers such as skeletal injury hinder the market growth.

COVID-19 Impact Analysis on Cardiac Troponin Market

The impact of COVID-19 is significant effected on the global cardiac troponin market. As per the article published in Nature Reviews Cardiology in October 2021, cardiovascular complications in patients with moderate-to-severe COVID-19 and evidence of cardiac injury (elevated troponin levels and reduced left ventricular ejection fraction. Patients with preexisting cardiovascular disease may be more susceptible to COVID-19 infection. They may be at increased risk of death, especially when patients present with elevated troponin T levels, where mortality may be three-fold higher than those without cardiovascular disease patients.

Also, those with COVID-19 may be at risk of developing cardiac complications, especially acute cardiac injury and arrhythmias; acute myocardial injury may be more common in patients with preexisting cardiovascular disease and associated with increased morbidity and mortality.

On the other hand, according to the American College of Cardiology, in 2020, the frequency and non-specific nature of abnormal troponin results among patients with COVID-19 infection, clinicians are suggested to only measure troponin if the diagnosis of acute MI is being evaluated in clinical environments. Without supporting evidence, an abnormal troponin should not be supposed to be evidence for an acute MI.

Cardiac Troponin Market Segmentation Analysis

The point-of-care testing segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)

By Type:

Troponin I

Troponin T

Others

By Location of Testing:

Laboratory Testing

Point of Care Testing

The point of care testing segment accounts for the largest market share. The rising adoption of point-of-care testing systems for health records is expected to boost the market over the forecast period. As per the article published in Practical Laboratory Medicine in November 2020, Accreditation and regulatory standards highlight the rising need to integrate POC Testing results into the patient's electric medical records. This promotes accessibility of POCT results, the ability to monitor and trend, prevents unnecessary repeat testing and provides evidence for patient outcomes.

As POCT results are used to make clinical decisions, it is important to document results with associated reference intervals, units of measurement, critical values if applicable, date and time of testing, and also be traceable to device serial number, operator identification number, reagent lot number, and quality control (QC) results. POCT results should also be clearly differentiated from other central laboratory results to avoid confusion and trending results from different analytical methodologies. POCT is currently routine in all hospitals and has become the standard for patient care in a variety of other healthcare settings. Cardiac troponin is accurately performed by POCT.

By Application:

Acute Coronary Syndrome

Myocardial Infarction

Congestive Heart Failure

Others

By End User:

Hospitals

Diagnostic Centers

Cardiac Troponin Market Geographical Share

North America region holds the largest market share of the global cardiac troponin market

By Region:

North America

Latin America

Europe

Asia Pacific

Middle East and Africa

North America dominates the market for cardiac troponin and is expected to show a similar trend over the forecast period. The market is driven by the factors such as increasing demand for diagnosis of cardiac disease and advancements in cardiac biomarkers.

As per the Centers for Disease Control and Prevention, 2020, in the United States about 20.1 million adults age 20 and older have CAD (about 7.2%). The rising the patients with cardiovascular disease leads to increasing demand for the market in the region which drives the market in the region.

In addition, the market players are offers the products in the United States region. For instance, Quidel Corporation provides TriageTrueTM High Sensitivity Troponin I Test for the quantitative determination of troponin I in EDTA anticoagulated whole blood and plasma specimens. The test is to be indicated as an aid in the diagnosis of myocardial infarction (MI) for use with Quidel's Triage MeterPro instrumented system.

Cardiac Troponin Market Companies and Competitive Landscape

The cardiac troponin market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Biomerieux, Beckman Coulter, Siemens Healthcare, Roche, Fujirebio, Abbott, LifeSign, Alere, and Singulex, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the cardiac troponin market globally.

For instance,

In April 2021, Roche announced a series of five new intended uses for two key cardiac biomarkers (cTnT-hs), using the Elecsys technology, which has the NT-proBNP and highly sensitive cardiac troponin T.

Biomerieux

Overview:

Biomerieux is a French multinational biotechnology organization founded in 1963 and headquartered in France. It offers innovative products and services to meet the need for global solutions.

Product Portfolio:

VIDAS High sensitive Troponin I: It is a useful aid to optimize the management of Acute Coronary Syndromes (ACS). It provides a high level of performance for diagnosis and risk stratification and delivers a diagnosis within 2 hours.

The global Cardiac Troponin market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising demand for cardiac biomarkers to diagnose cardiovascular diseases
      • 4.1.1.2. Rising prevalence of acute coronary syndrome
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of required precision for collecting samples
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Troponin I*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
  • 7.3. Troponin T

8. By Location of Testing

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
    • 8.1.2. Market Attractiveness Index, By Location of Testing
  • 8.2. Laboratory Testing*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
  • 8.3. Point of Care Testing

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Acute Coronary Syndrome*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
  • 9.3. Myocardial Infarction
  • 9.4. Congestive Heart Failure
  • 9.5. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030
  • 10.3. Diagnostic Centers
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2023-2030, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Location of Testing
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking

13. Company Profiles

  • 13.1. Biomerieux*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Beckman Coulter
  • 13.3. Siemens Healthcare
  • 13.4. Roche
  • 13.5. Fujirebio
  • 13.6. Abbott
  • 13.7. LifeSign
  • 13.8. Alere
  • 13.9. Singulex(*LIST NOT EXHAUSTIVE)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us